Aconitum Napellus Whole Bryonia Alba Root Eucalypt
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Aconitum Napellus Whole Bryonia Alba Root Eucalypt
- Homeopathic Multi-Component Combination (Aconitum/Bryonia/Pelargonium): TxGNN Prediction Unavailable
Homeopathic Multi-Component Combination (Aconitum/Bryonia/Pelargonium): TxGNN Prediction Unavailable
One-Sentence Summary
This submission contains a complex 8-component homeopathic botanical combination — including Aconitum napellus, Bryonia alba, Pelargonium sidoides, and Gelsemium sempervirens — classically associated with influenza-like illness and upper respiratory tract infections. The TxGNN model was unable to generate any repurposing predictions for this candidate, most likely because the combination lacks a standard DrugBank identifier required for knowledge graph traversal. As a result, no evidence-based repurposing direction can be established at this time, and the overall assessment is classified as Hold pending structural data remediation.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not established (no regulatory approvals on record) |
| Predicted New Indication | Not available — TxGNN returned no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — model prediction unavailable; no supporting studies for the combination |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
No TxGNN prediction was generated for this candidate, so a standard mechanism-to-indication inference cannot be made.
The 8 components are all well-known homeopathic materia medica ingredients. Based on their classical indications and the limited conventional pharmacology available:
- Pelargonium sidoides (EPs 7630 extract) is the most evidence-backed component, with multiple randomised controlled trials supporting its use in acute bronchitis and upper respiratory tract infections. It appears to act via immunomodulatory and direct antiviral mechanisms.
- Eupatorium perfoliatum, Gelsemium sempervirens, and Aconitum napellus are traditionally indicated for influenza-like illness (fever, myalgia, chills, fatigue).
- Bryonia alba and Phosphorus target cough and lower respiratory symptoms.
- Eucalyptus globulus is associated with mucolytic and mild antimicrobial activity in the upper airways.
- Ipecac (in sub-emetic homeopathic dose) is traditionally used for nausea and spasmodic cough.
As a combination, the product profile is most consistent with acute respiratory infections / influenza-like illness (ILI), but this inference is based on component-level knowledge, not on TxGNN graph scoring. No repurposing direction beyond this original cluster can be formally proposed without a valid drug node in the knowledge graph.
Clinical Trial Evidence
Currently no related clinical trials registered for this multi-component combination as a single entity.
Note: Individual components have been investigated separately. Pelargonium sidoides (EPs 7630) has the strongest trial base (acute bronchitis, URTI). Searches against the combination as a whole returned no matching NCT records.
Literature Evidence
Currently no related literature available for this combination as a unified drug entity.
Individual component literature (particularly for Pelargonium sidoides) exists but is not attributable to the combination product without a consolidated DrugBank or CAS identifier.
Safety Considerations
Please refer to the package insert for safety information.
All safety fields (key warnings, contraindications, drug-drug interactions) returned no data for this combination. Because several components carry known pharmacological risks in non-homeopathic doses — notably Aconitum napellus (cardiotoxic alkaloids), Gelsemium sempervirens (strychnine-related alkaloids), and Ipecac (emetine cardiotoxicity) — a formal toxicology review is strongly recommended before any clinical development proceeds.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN pipeline requires a resolvable DrugBank ID to anchor the drug node in the knowledge graph; because this combination carries no DrugBank identifier and no original indication record, the model returned zero predictions. Without at least one prediction, there is no repurposing hypothesis to evaluate.
To proceed, the following is needed:
- Assign a DrugBank ID or decompose into individual components — Run TxGNN separately for each of the 8 components (especially Pelargonium sidoides DB09228 and others with known IDs) and aggregate predictions at the combination level.
- Establish original indication — Document the traditional or regulatory indication for this combination in at least one jurisdiction (e.g., Germany’s Commission E monograph, EMA HMPC opinion, or published homeopathic pharmacopoeia entry).
- Safety review — Given the presence of Aconitum, Gelsemium, and Ipecac, obtain a formal toxicology assessment covering dose-dependent risks before any repurposing direction is pursued.
- Obtain package insert / SPC — Required to satisfy the blocking data gap (DG001) and enable S1 safety evaluation.
- MOA mapping — Query DrugBank for each individual component to populate the mechanism-of-action field (DG002) and support future knowledge graph traversal.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.